ArticleBritish journal of cancer2024

Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.

Danka Sinikovic Zebic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.